A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of Varlitinib Plus Capecitabine Versus Placebo Plus Capecitabine in Patients With Advanced or Metastatic Biliary Tract Cancer as Second Line Systemic Therapy

Trial Profile

A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study of Varlitinib Plus Capecitabine Versus Placebo Plus Capecitabine in Patients With Advanced or Metastatic Biliary Tract Cancer as Second Line Systemic Therapy

Recruiting
Phase of Trial: Phase II/III

Latest Information Update: 06 Aug 2018

At a glance

  • Drugs Varlitinib (Primary) ; Capecitabine
  • Indications Adenocarcinoma; Biliary cancer; Cholangiocarcinoma; Gallbladder cancer; Periampullary cancer
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms TreeTopp
  • Sponsors ASLAN Pharmaceuticals
  • Most Recent Events

    • 06 Aug 2018 According to an ASLAN Pharmaceuticals media release, Study is on track to report topline data on varlitinib as second line treatment for biliary tract cancer in 2019.
    • 05 Jun 2018 Trial design presented at the 54th Annual Meeting of the American Society of Clinical Oncology.
    • 02 Jun 2018 Planned number of patients changed from 482 to 490.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top